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Summary 
The present study was performed in order to evaluate the effects of the selective 02-
adrenoceptor antagonist 6-chloro-2,3,4,5-tetrahydro-3-methyl-1H-3-benzazepine (SK&F 
86466) on dermorphin-induced analgesia, respiratory depression and inhibition of 
locomotor activity in the conscious rat. Intracerebroventricular (icv) administration of 
dermorphin (3 nmol/rat) decreased respiration rate and relative ventilatory minute volume 
maximally by 38 % and 50 % of baseline respectively. SK&F 86466 dose-dependently 
reversed the dermorphin-induced depression of ventilatory parameters, while SK&F 
86466 exerted no effect on dermorphin-induced analgesia or depression of locomotor 
activity due to catalepsia. It appears, therefore, that a 2-adrenoceptors selectively interact 
with Jl2-opioid-receptor mediated effects, such as respiratory depression, but are not 
involved in the modulation of Jl,-opioid-related effects, such as supraspinal analgesia and 
depression of locomotor activity. 
The depression of vital cardiorespiratory functions poses the major limitation for the therapeutic 
use of opiates and represents the primary underlying cause of fatalities due to overdosage among habitual 
drug abusers (1). The biological actions of morphine and enkephalins are mediated through multiple 
opioid receptors, termed Jl-, ö-, epsilon-, (1-, and K-opioid receptors. Additionally, two subtypes of Jl-
receptors, Jl,- and Jl2- binding sites, were identitied based on their relative selectivity for morphine and 
enkephalins (2). The wreceptor subtypes were further suggested to mediate different functions: While 
Jl,-opioid binding sites seem to be involved in morphine-induced supraspinal analgesia, the opiate-related 
respiratory depression and spinal analgesia, at least in part, appear to be mediated through Jl2-binding 
sites (3,4,5). In addition to opioids, other neurotransmitters are known to induce analgesia. Thus, 
systemic administration of a2-adrenoceptor agonists produces analgesia in various species (6,7,8). 
Moreover, central a2-adrenoceptor activation with clonidine results in cardiorespiratory depression, 
which is attenuated by the a 2-adrenoceptor antagonist yohimbine (9,10,11). It appears, therefore, that 
the biological effects of opioids, especially those mediated by thti Jl2-subclass, and those related to a 2 
adrenergic receptors are similar in a qualitative sense, suggesting the involvement of a common 
mechanism. 
The heptapeptide Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, dermorphin, a specific Jl-opioid agonist, 
elicits analgesia and respiratory depression in pico- to nanomolar doses with an increased potency 
compared to morphine (5). In order to investigate, whether O2-adrenoceptor antagonism would interact 
with dermorphin-induced analgesia and respiratory depression, we conducted aseries of experiments in 
conscious, unrestrained rats, using apretreatment schedule with 6-chloro-2,3,4,5-tetrahydro-3-methyl-
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IH-3-benzazepine (SK&F 86466), a specific Q'2-adrenoceptor antagonist which was shown, in contrast 
to other functionally related agents, such as idazoxan, to be devoid of a notable affinity to central 
imidazole binding sites (12,13). 
Methods 
Surgical Procedures. Male Spraque-Dawley rats (270-358 g; Taconic Farms, Germantown, NY) 
were anesthetized with an intramuscular injection of ketamine (130 mg/kg) and acepromazine (1.3 
mg/kg). A stainless steel guide cannula for icv injections was glued over the right cerebral hemisphere 
(Eastman 910 Adhesive) at the following coordinates: -0.8 mm AP, 1.2 mm LA from bregma. The right 
external jugular vein was then cannulated using PE-50 tubing filled with heparinized saline for in-
travenous (iv) drug administrations. The tubing was exteriorized at the neck of the animal and sealed by 
means of an electrical cauter iron. The animals were allowed to recover for at least 36 hours before the 
onset of the experiment. 
On the experimental day, different groups of animals received a single iv injection of SK&F 
86466 (1 or 5 mg/kg) or 0.9% saline solution 20 minutes before an icv injection of 10 /LI ofthe Wopioid 
agonist dermorphin or artificial cerebrospinal fluid (CSF) respectively. The icv injections were performed 
manually over 10 to 15 seconds using a 30 gauge cannula of7.5 mm length which was inserted into the 
right cerebral ventricle via the previously implanted guide cannula and aSO /LI Hamilton syringe. At the 
end of the experiment the location of the icv administration was visualized by injection of methylene 
blue. 
Analgesia. Analgesia was monitored using a tail-flick apparatus (Socrel lnc., Milano, Italy). A 
12 second cut-off time was chosen in order to limit temperature-derived tissue damage. Tail-flick 
response times as a measure of analgetic activity are represented as percentage of the maximal possible 
effect (% of MPE) following the equation: 
post drug latency - predrug response latency 
% ofMPE = 
cut-off time - predrug response latency x 100 
At the start ofthe experiment, 0.9% saline solution (100 /LI/1oo g body weight) or SK&F 86466 
(5 mg/kg) were administered iv, followed by an icv injection of 30 (n=6) or 100 (n=6) pmol/rat 
dermorphin or artificial CSF (n=3) after 20 minutes. The analgesia induced by dermorphin was assessed 
at 15, 30, 60, 90, 120, and 150 minutes after icv injection. 
Respiration. Respiration rate (t), relative tidal volume (rV T)' O2 consumption, and CO2 
production were measured in conscious, unrestrained animals using the OXYMAX '85 system 
(Columbus lnstr., Columbus, OH). The system consists ofthree transparent plexiglass chambers of6.55 
liters volume each with a constant flow of 2 liters of room air per minute. Two of the chambers are used 
for the actual recording of ventilatory parameters, while the third serves as a reference. Alternate 
measurements are performed every 2 minutes. The respiration rate is determined based on the frequency 
(respirations/minute, rpm) of pressure changes due to the ventilatory movements of the animal's thorax. 
The tidal volume (V T) is recorded as an integral of pulses, which is proportional to the amplitude of the 
pressure changes and compared to the pulse count in the first sampIe measure of the experiment. Tidal 
volume is therefore expressed as relative tidal volume (rVT) in arbitrary units. The relative ventilatory 
minute volume (rV J is calculated as the arithmetical product of fand rV T. The O2 and CO2 contents of 
the animal chambers are measured against the reference chamber. The arithmetical differences are then 
expressed as O2 consumption and CO2 production respectively. 
The animals were placed into the chambers at the onset of the experiment. After 75 minutes, a 
period which is sufficient for the animals to get accustomed to the new environment, SK&F 86466 
(1 mg/kg, n=6; 5 mg/kg, n=6) or 0.9 % saline solution (100 /Ll/1oo g body weight, n=7) was injected 
iv over aperiod of 30 seconds. Respiratory parameters were monitored for an additional 20 minutes, 
before both groups received a single icv injection of dermorphin (3 nmol/rat) or artificial CSF. The 
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measurement of respiratory effects was thereafter continued for 115 minutes; the overall recording time 
per experiment was 3.5 hours. The resu[ts are expressed as changes in percent of baseline va[ues which 
were obtained as averages of the parameter va[ues during the [ast 30 minutes preceding the iv drug 
injection, when the anima[s were in resting conditions. The effects of the pretreatments with SK&F 
86466 or vehic1e were assessed as areas under the curves depicting the parameter changes over time (20 
min), using a trapezoidal method. This approximative procedure consists of the summation of the areas 
of various trapezoids fitted to the curve segment representing the pretreatment period. 
Locomotor activity. SimuItaneous[y to the measurement of respiratory parameters, [ocomotor 
activity (LA) of the anima[s was monitored, using two Digiscan Optica[ Sensor Activity Monitors 
(Co[umbus Instr., Co[umbus, OH). The estimation of [ocomotor activity is based on the interruption of 
infrared light beams, which are [ocated 2.5 cm above ground, caused by the [ocomotion of the animals 
in the OXYMAX'85 system chambers. The data were collected as counts per 2 minutes. The effects of 
pretreatment with SK&F 86466 (5 mg/kg) or saline iv and treatment with dermorphin or CSF icv were 
ca[cu[ated as sums of counts du ring the respective observation periods. 
Statistics. Data reduction for statistical evaluation and graphing purposes was performed by 
averaging three consecutive samp[es. One way analysis of variance (ANOVA) followed by Tukey's test 
was used to analyze the effects of dermorphin vs. artificia[ CSF icv. The effects of the respective 
pretreatment-treatment combination over time within each group was assessed, using the ANOV A test 
for repeated measures (MANOVA). Differences of the curve areas during the period of iv pretreatment 
and maximal parameter changes due to different pretreatment-treatment combinations were compared 
using the Kruskal-Wallis procedure, followed by the Mann-Whitney-U test. Data are presented as means 
± S.E.M. 
Drugs. Dermorphin (peninsu[a) for icv injections was disso[ved in artificial CSF containing 127 
mM NaC[, 2.5 mM KCl, 1.3 mM CaC[2' and 0.9 MgC[2 in deionized water. SK&F 86466 was a 
generous gift from Dr. G. Z. Feuerstein, SmithKline Beecham Research and Deve[opment, King of 
Prussia, PA. For iv administration, SK&F 86466 was disso[ved in 0.9% saline solution. 
Analgesia. Dermorphin doses of 30 and 100 pmol/rat induced a potent, dose-related analgesia 
(Fig. 1). The maximum analgetic effects were reached approximate[y 30 to 60 minutes after icv 
injection. A[though treatment with the a2-adrenoceptor antagonist SK&F 86466 (5 mg/kg) appeared to 
potentiate the ana[getic effect of the [ow dose dermorphin treatment somewhat, no statistical significance 
cou[d be detected between the SK&F 86466 and the saline pretreated groups of animals. Additionally, 
SK&F 86466 iv, followed by artificial CSF icv did not exhibit analgetic properties (Fig. 1). 
Respiration. Baseline va[ues for all respiratory parameters are shown in tab[e 1. Pretreatment 
with SK&F 86466 produced a dose-related decrease of the curve areas for f (Fig. 2, P < 0.001, Kruska[-
Wallis) as compared to the stimulation of f seen after saline administration. This stimulation is most 
[ikely based on the environmental stress due to the handling of the animals during the iv injection 
procedure. The effect on f subsided about 20 minutes after injection and was accompanied by a 
counterba[ancing increase ofrV T in anima[s receiving 5 mg/kg SK&F 86466 (Fig. 2, p< 0.01, Kruska[-
Wallis). Thus no change of rVE could be detected in this group (Fig. 2). A similar change of rVT was 
not apparent after 1 mg/kg SK&F 86466 iv, [eading to a reduction of rVE (p<0.05, Kruskal-Wallis). 
Additionally, O2 consumption but not CO2 production after SK&F 86466 iv differed significantly from 
saline controls (p < 0.05, Kruska[-Wallis). 
Icv injection of dermorphin (3 nmol/rat) caused significant decreases of f (Fig. 3), rV E (Fig. 3), 
O2 consumption, and CO2 production (p<0.05 vs. CSF icv, Tukey's test), which became maximal at 
60 minutes after the administration. The rVT on the other hand was significantly e[evated after der-
morphin icv (p<0.05 vs. CSF icv, Tukey's test). Maximum effects were assessed and compared by 
averaging 6 samp[e va[ues derived from the region of maximal change of each parameter (between 65 
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and 75 minutes after the icv injection of dermorphin, Fig. 3). Dermorphin icv significantly reduced rVE 
and f by 38 % and 50 % respectively, when compared to CSF icv controls (p<0.05, Kruskal-Wallis, 
Fig. 4). Moreover, O2 consumption and CO2 production were reduced by 26 % and 22 % (n.s. vs. CSF 
icv). 
0-0 DM 30 (6) 
fj.-fj. DM 100 (6) 
W'100 
~ 80 
~ 60 
'-" 
o 40 
.~ 20 
0"1 0 
o 
1::-20 
o 
.-. SK&F 86 466 + DMJO (6) 
A-A SK&:F 86466 + DM100 (6) 
+-+ SK&:F 86 466 + CSF (3) 
-40~--~--~--~~--~--~ 
o 30 60 90 120 150 
time (min) 
FIG.1 
Effect of SK&F 86466 on dermorphin (DM)-induced analgesia. An iv injection 
of SK&F 86466 (5 mg/kg, n=6) or vehicle (saline, n=6) was administered 20 minutes 
before an icv injection of 30 or 100 pmol/rat of dermorphin or 10 /LI artificial CSF 
(n=3). The 0 time point on the abscissa denotes the icv injection. 
TABLE 1 
rVE rVT f O2 cons. CO2 prod. 
saline iv 112±15 149±18 76± 3 1035±82 889 ± 30" CSF icv 
saline iv 265±94 270±86 94± 4 1189±49 1119±29 dermorphin icv 
SK&F 86466 iv (5 mg/kg) 68± 9 93±13 74± 5 970±22b 909±21b CSF icv 
SK&F 86466 iv (1 mg/kg) 164±21 183±20 89± 3 1092±26 986± 19" dermorphin icv 
SK&F 86466 iv (5 mg/kg) 201±62 225±66 88± 3 1167±26 1052±24 dermorphin icv 
Table 1: Synopsis of Parameter Baseline Values (n=5-7). The dimensions for the 
respiratory rate (t) and O2 consumption (02 cons.) or CO2 production (C02 prod.) are 
respirationslminute (rpm) and ml/kg/min respectively. The relative tidal volume (rVT) is 
expressed in arbitrary units in percent of the first sampie initially recorded at the onset 
of the experiment. Therefore the rVE is expressed in rpm. a) denotes a significant 
difference between the groups receiving dermorphin icv (P < 0.01, Kruskal-Wallis); b) 
compares the groups receiving SK&F 86466 (5 mg/kg iv) as pretreatment (p<0.01, 
Kruskal-Wallis). 
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Pretreatment with SK&F 86466 potently and dose-dependently abolished or even reversed the 
effects of dermorphin on ventilation (Fig. 3&4). While values for f after dermorphin icv in SK&F 86466 
(5 mg/kg) pretreated animals did not differ from baseline values taken at 60 minutes after the onset of 
the experiment, rV E (P < 0.05, MANOVA), O2 consumption (P < 0.05, MANOVA), and CO2 production 
(p<O.OOl, MANOVA) were significantly elevated. 
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FIG.2 
Effects of SK&F 86466 (1 mg/kg, n=6; 5 mg/kg, n= 11) or vehicle (n= 12) 
treatment on respiratory parameters and locomotor activity. Areas of the curves (Ieft 
ordinate) representing the ventilatory changes from baseline during a 20 minute 
observation period after the iv injection of SK&F 86466 or saline were calculated using 
a trapezoidal method. Locomotor activity (LA) was assessed as sum of counts over the 
same 20 minute period (right ordinate) .• ) = p < 0.05, •• ) = p < 0.01, and ••• ) = 
p < 0.001 (vs. saline, Kruskal-Wallis). 
FIG.3 
Time course of the changes of relative ventilatory minute volume (rV J and 
respiration rate (f) in percent of baseline after the icv injection of dermorphin (3 
nmollrat) in saline (n=7) or SK&F 86466 (5 mg/kg, n=6) treated rats. The time point 
o on the abscissa denotes the icv injection. Data points represent mean values of three 
consecutive sampies. 
Locomotor activity. Inj ection of 5 mg/kg of SK&F 86466 caused a significant decrease of LA 
counts when compared to saline controls (p < 0.01, Mann-Whitney-U, Fig. 2). No significant differences 
116 ~-Opioids and u2-Antagonists Vol. 49, No. 2, 1991 
between the groups were found after the injection of artificial CSF or dermorphin icv when the LA was 
calculated over the entire observation period following the icv injections. This result apparently was due 
to an initial activation of LA after the injection of both, artificial CSF or dermorphin, which lasted about 
30 minutes. After this time the animals receiving dermorphin icv appeared clearly cataleptic, while the 
control animals (CSF icv) still exhibited periodic bursts of LA. Thus, the LA after dermorphin was 
almost entirely suppressed between 30 and 115 minutes after icv administration of dermorphin (p < 0.01 
vs. CSF icv, Kruskal-Wallis, Fig. 4). Pretreatment with SK&F 86466 did not modify the effect on 
either, CSF or dermorphin treated animals. 
300 50 500 
~ scline+CSF 
* !1llA 5 mg!kg+CSF 
........... 200 Cl scline+Ot.4 25 250 1 mg/.kg+OM ~ 
-.....J - 5 mgi'kg+OM 
X 100 0 0 C 
E 
<J 0 -25 
-100 
rVr 
-50 
FIG.4 
Maximum changes of ventilatory parameters and locomotor activity. Ventilatory 
data represent means ± S.E.M. of six successive sampies taken from the region of the 
maximum effect of dermorphin (DM) icv. The groups consist of n=5 (saline iv, CSF 
icv), n=5 (5 mg/kg SK&F 86466 iv, CSF icv), n=7 (saline iv, DM icv), and n=6 (1 
and 5 mg/kg SK&F 86466 iv, DM icv) rats. Locomotor activity (LA, right ordinate) was 
calculated as sum of LA counts over a 85 minute period following 30 minutes after the 
icv injection of dermorphin .• ) = p < 0.05 (Kruskal-Wallis) denotes significant 
differences between the saline or SK&F 86466 pretreated animals, while + ) = p < 0.05 
and ++ ) = p < 0.01 (Kruskal-Wallis) represent statistical significance between the groups 
receiving dermorphin (3 nmol/rat) or artificial CSF after an iv pretreatment with 0.9 % 
saline solution. 
Discussion 
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The present study demonstrates the interaction of an exz-adrenoceptor antagonist, SK&F 86466, 
with the respiratory depressant, but not the analgetic and locomotor depressant properties of icv ad-
ministered dermorphin, a jl-opioid receptor specific agonist, in conscious rats. Dermorphin produced a 
significant depression of f. A concomitant increase of V T was insufficient to counteract the decrease of 
f, resulting in a significant depression of VE• Although decreases in both, ~ consumption and CO2 
production were observed after dermorphin treatment, these effects did not statistically differ from 
controls receiving artificial CSF icv. In the case of CO2 production, however, this lack of a significant 
depression may have been due to a lower baseline level in the CSF treated group. SK&F 86466 potently 
reversed the depression of rV E, f, and CO2 production caused by dermorphin. No significant effects, 
however, were detectable on rVT, O2 consumption, the depression oflocomotion, and, most importantly, 
on dermorphin-induced analgesia. 
Studies using biochemical, anatomical, and pharmacological approaches suggest that multiple 
opioid receptors mediate the effects of morphine in the central nervous system (for review see 2). These 
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receptors may be separated, among other criteria, according to their differential affinities for morphine 
and enkephalin. While 1l2- and o-opioid receptors exert a high affinity for either morphine or enkephalin 
respectively, the J.ll-sites bind both with equally high affinity (2). Functionally, J.ll- and J.l2-opioid binding 
sites appear to be involved in the mediation of different opiate-induced biological effects. Thus, J.l1-opioid 
binding sites seem to mediate supraspinal analgesia (2,5). This hypothesis is corroborated by evidence 
showing that J.l1-opioid binding sites are preferentially located in CNS structures, which may represent 
the anatomical correlates for opiate-induced supraspinal analgesia (14,15,16). Additionally, recent 
evidence (17) revealed a selective decrease of J.ll binding sites in the aforementioned CNS locations in 
a mouse strain which appears insensitive to morphine analgesia. Further, J.ll-opioid binding sites may also 
mediate the stimulation of respiration and locomotor activity in rats after icv administration of low doses 
ofthe unselective j.l-agonist dermorphin, since these effects were effectively abolished after pretreatment 
with the selective J.ll-antagonist naloxonazine (5). Similarly, opiate-induced catalepsy was drastically 
antagonized with another J.ll-selective antagonist, naloxazone, indicating that both, locomotor stimulation 
and catalepsy may be mediated through a J.ll-opioid receptor related mechanism (18). 
In contrast, J.l2 sites in addition to 0- and K-receptors appear to mediate the opiate-induced spinal 
analgesia, since naloxonazine has no effect on the antinociception produced by intrathecal (it) injections 
of the J.I-selective agonist [D-Ala2, N-methyl-Phe4 , GlyS-ol]enkephalin (DAMGO), but effectively 
prevents the analgesia induced by DAMGO icv (4). Additionally, the respiratory depressant effect of 
opiates is attributed to the ll2-opioid binding site (2,5). Thus, the unspecific J.I-opioid antagonist naloxone 
blocked the hypoxemia and hypercapnia due to morphine-induced respiratory depression, while the J.ll-
selective antagonist naloxonazine was ineffective (19). 
An increasing amount of evidence emphasizes the opiate-Iike actions of a 2-adrenoceptor-related 
compounds such as cIonidine. Thus, systemic administration of the a2-adrenoceptor agonist cIonidine has 
been shown to produce analgesia in various species (6,7,8). Interestingly, cIonidine does not elicit any 
antinociceptive effects, when administered locally into the periaquaeductal grey, which is presumed to 
be crucially involved in the generation of supraspinal, J.l1-opioid-related analgesia (20). On the other 
hand, intrathecal injections of cIonidine and norepinephrine exhibited potent antinociceptive actions, 
which were antagonized with the selective a 2-adrenoceptor antagonist yohimbine, suggesting that a 2-
adrenoceptors may mediate the analgetic response to catecholamines on a spinal level (16). Indeed, 
descending, catecholaminergic projections from the locus coeruleus (LC) to various spinal segments 
appear to be involved in the generation of spinal analgesia (21). Thus, LC lesions were accompanied by 
a decrease of spinal norepinephrine content, leading to a compensatory upregulation of spinal a2-
adrenoceptors combined with an enhancement of the antinociceptive effect of an a 2-adrenoceptor agonist 
(21). Interestingly, administration of the a 2-adrenoceptor agonist ST-91 (it) was shown to potentiate the 
analgetic effect of morphine (it), suggesting a synergistic interaction of spinal J.I-opioid and a2-
adrenoceptor mechanisms (22). 
The data presented in this study not only add to the already existing body of evidence concerning 
an opioid-catecholamine interaction, but further establish the basis for a putative mechanism thereof. 
Thus, pretreatment ofthe animals with SK&F 86466, a specific a 2-adrenoceptor antagonist (12), did not 
affect the presumably J.lcopioid receptor mediated analgesia and catalepsy as shown by its lack of effect 
on the dermorphin-induced depression of LA. The ll2-opioid receptor related respiratory depression, on 
the other hand, was effectively antagonized. The elevation of rVE, O2 consumption, and CO2 production 
above baseline levels after dermorphin icv in SK&F 86466 pretreated rats, may be due to the remaining 
action of dermorphin on J.ll-opioid receptors, which were shown to mediate dermorphin-induced respi-
ratory stimulation (5). The fact that SK&F 86466 pretreatment did not affect dermorphin-induced 
analgesia, however, does not precIude an interaction of the a 2-adrenoceptor antagonist on this opioid 
effect under different experimental conditions. Thus, icv injection of dermorphin presumably induces 
a supraspinal, J.ll- receptor mediated analgesia, which may mask an effect on the spinal antinociception 
elicited by SK&F 86466. A J.l2-mediated, spinal component of the analgesia induced by an it injection 
of dermorphin may very weil be subject to an antagonizing effect of SK&F 86466. 
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The mechanisms, involved in the interaction between Jlz-opioids and lX2-adrenoceptor agonists 
or antagonists can at this point only be speculative. Recent evidence suggests an involvement of central 
adrenergic pathways in the modulation of respiratory patterns. Thus, while ß-adrenergic agents and lX2-
adrenoceptor antagonists were shown to stimulate respiratory activity, lX2-adrenoceptor agonists exerted 
a depressing effect (9,11,23,24). Furthermore, the A5 noradrenergic ceU group, located in the 
ventrolateral pons may represent an anatomic origin of noradrenergic fibers, modulating the medullary, 
respiratory rythm generator, predominantl y in form of a tonic inhibition (24). Thus, electrical stimulation 
of the A5 region lead to a prominent inhibition of respiration, which was blocked by the az-adrenoceptor 
antagonists yohimbine and idazoxan (24). Therefore, it is conceivable that treatment with SK&F 86466 
may antagonize norepinephrine action at postsynaptic lX2-adrenoceptors, located on medullary neurons, 
which are involved in the generation of respiratory rythms. The blockade of presynaptic lX2-adrenoceptors 
by SK&F 86466 would cause an increased norepinephrine release and would thus be expected to enhance 
the respiratory depression induced by dermorphin. Furthermore, it appears unlikely that the observed 
effects are due to a mere physiological antagonism, since no effects on rVB were observed after iv 
administration of SK&F 86466 (Fig. 4). It is yet unclear, however, whether IL-opioids depress respiration 
through a direct, IL receptor-mediated action at medullary neurons, or indirectly through the modulation 
of noradrenergic input to these ceUs. The mechanism underlying the described antagonism may involve 
an interaction at the receptor level or at second messenger systems. A receptor based mechanism of 
interaction is supported by the colocalization of low affinity type lX2-adrenoceptors and Jlz-opioid binding 
sites (25,26). The mode of interaction at the 1L2-0pioid receptor is probably not competitive, since 
azidomorphin and other opiates show only weak ability to displace pH]clonidine from its binding sites 
in rat cortex (27). However, a noncompetitive mode of action has to be considered as weIl, whereby lX2-
adrenoceptors may modulate the affinity and/or density of Jlz-opioid receptors and vi ce versa in form of 
a (Ilz/lXz) receptor complex. Interaction on the second messenger level may also explain the antagonistic 
properties of SK&F 86466 on Jlz-mediated phenomena, since in both, brain membrane preparations and 
certain ceU lines, opiate and lX2-adrenergic receptors are coupled to adenylate cyclase via G-proteins 
(28,29) emphasizing a possible mode of interaction through modulation of common, intracellular 
mechanisms. While the molecular mechanisms underlying the interaction of az-adrenoceptor agonists or 
antagonists and 1L2-opioid receptor-mediated responses are yet to be identified, the presented data indicate 
a potential, novel concept in the treatment and prophylaxis of opiate-induced respiratory depression at 
a maintained level of antinociception. 
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